Janssen Vaccines & Prevention B.v.

Crucell Holland B.v.

Aeras Global Tb Vaccine Foundation

Katarina Radosevic

Jan Willem Meijberg

Antonietta Impagliazzo

Ronald Vogels

Jehangir Wadia

Robert Anthony Williamson

Jaap Goudsmit

Gabriel Pascual

Michelle Wagner

Zhaoqing Ding

Jerald C Sadoff

David M Hone

Jan Wilem Meijberg

Menzo Jans Emco Havenga

Jort Vellinga

Jerôme H H V Custers

Stefan Loverix

Robert H E Friesen

Myra N Widjojoatmodjo

Yasir A W Skeiky

Myra Noorely Widjojoatmodjo

Philippe Alard

Yasir Abdul Wahid Skeiky

Jerome Hhv Custers

Menzo J E Havenga

Robert Heinz Edward Friesen

Ramon Roozendaal

Ariane Rodriguez-Munoz

Angelique Alida Corina Lemckert

Menzo Jans Emko Havenga

Jerôme HHV Custers

Anna Roos

Yasir Abdul Skeiky

Ariane Rodriguez Munoz

Angelique Alida Lemckert

Menzo Jans Havenga

The invention relates to antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The invention also relates to diagnostic, prophylactic and therapeutic methods using anti-tau antibodies.

Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau

The disclosure relates to antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The disclosure also relates to diagnostic, prophylactic and therapeutic methods using anti-tau antibodies.

Antibodies and antigen-binding fragments that specifically bind to  microtubule-associated protein tau

Provided are influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment comprising the amino acids from position 1 to position x, preferably from position p to position x, of the HA1 domain, covalently linked by a linking sequence of 0-50 amino acid residues to an HA1 C-terminal stem segment, comprising the amino acids from position y to and including the C-terminal amino acid of the HA1 domain; and (b) an influenza hemagglutinin HA2 domain, wherein the hemagglutinin stem domain polypeptide is resistant to protease cleavage at the junction between HA1 and HA2, and wherein one or more amino acid of the amino acids at positions 337, 340, 352, 353, 402, 406, 409, 413 and/or 416 have been mutated, as compared to the corresponding positions in wild-type influenza HA.

Influenza virus vaccines and uses thereof

Provided herein are influenza hemagglutinin stem domain polypeptides, methods for providing hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use, in particular in the detection, prevention and/or treatment of influenza.

Provided herein are multimeric influenza hemagglutinin stem domain polypeptides, methods for providing hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use, in particular in the detection, prevention and/or treatment of influenza.

The present disclosure provides influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment, covalently linked by a linking sequence of 0-50 amino acid residues to an HA1 C-terminal stem segment, and (b) an influenza hemagglutinin HA2 domain, wherein on or more amino acids in the HA2 domain have been mutated. Also provided are nucleic acids encoding the polypeptides, compositions comprising the polypeptides and/or nucleic acid molecules, as well as methods of their use, in particular in the detection, prevention and/or treatment of influenza.

Described are methods for inducing an immune response in a subject against an antigen from a malaria-causing parasite, preferably, the method comprising: (i) administering to a subject a priming composition comprising adjuvanted proteinaceous antigen-comprising circumsporozoite (CS) protein or an immunogenic part thereof from a malaria-causing parasite; (ii) administering to the subject a first boosting composition comprising a recombinant adenovirus vector that comprises nucleic acid encoding CS protein or immunogenic part thereof from a malaria-causing parasite; and (iii) administering to the subject a second boosting composition comprising a recombinant adenovirus vector that comprises nucleic acid encoding CS protein or an immunogenic part thereof from a malaria-causing parasite, wherein either the first boosting composition comprises a recombinant adenovirus vector of serotype 35 (Ad35) and the second boosting composition comprises a recombinant adenovirus of Ad26, or wherein the first boosting composition comprises a recombinant adenovirus vector of Ad26 and the second boosting composition comprises a recombinant adenovirus of Ad35.

Heterologous prime boost vaccination regimen against malaria

Provided is a vaccine against respiratory syncytial virus (RSV), comprising a recombinant human adenovirus of serotype 26 that comprises nucleic acid encoding a RSV F protein or immunologically active part thereof.

Vaccine against RSV

Provided is a vaccine against respiratory syncytial virus (RSV), comprising a recombinant human adenovirus of serotype that comprises nucleic acid encoding a RSV F protein or immunologically active part thereof.

The invention relates to vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding for at least two antigens from one or more tuberculosis-causing bacilli. Also described is the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. Further described is the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease.

Multivalent vaccines comprising recombinant viral vectors

Described are vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding at least two antigens from one or more tuberculosis-causing bacilli. Also described is the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. Also described is the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease.

Growing community of inventors

Nootdorp, Netherlands

Katarina Radosevic